The progression rate of aortic stenosis: key to tailoring the management and potential target for treatment.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
pubmed:
3
11
2020
medline:
1
2
2022
entrez:
2
11
2020
Statut:
ppublish
Résumé
Aortic stenosis is the most frequent valvular disease to require intervention in the western world and has always been featured as a progressive disease. The rate of progression can be assessed by carefully performed Doppler echocardiography and can vary greatly between individuals with a profound impact on prognosis. Unfortunately, the determinants of disease progression had been insufficiently studied and remain challenging to define, particularly in the outpatient setting. Multiple factors have been proposed and tested, but at present, there are no proven therapies to slow the course of the stenotic process. Heart valve clinics may be particularly important to define the progression rate and tailor follow-up and management at an individual level. This review enlightens knowledge and gaps regarding the progression-rate of aortic valve stenosis, from the historical perspective to the molecular one.
Identifiants
pubmed: 33136810
pii: 01244665-202111000-00002
doi: 10.2459/JCM.0000000000001126
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
806-812Informations de copyright
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Vaslef SN, Roberts WC. Early descriptions of aortic valve stenosis. Am Heart J 1993; 125 (5 Pt 1):1465–1474.
Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24:1231–1243.
Cheitlin MD, Gertz EW, Brundage BH, Carlson CJ, Quash JA, Bode RS Jr. Rate of progression of severity of valvular aortic stenosis in the adult. Am Heart J 1979; 98:689–700.
Bogart DB, Murphy BL, Wong BY, Pugh DM, Dunn MI. Progression of aortic stenosis. Chest 1979; 76:391–396.
Wagner S, Selzer A. Patterns of progression of aortic stenosis: a longitudinal hemodynamic study. Circulation 1982; 65:709–712.
Davies SW, Gershlick AH, Balcon R. Progression of valvar aortic stenosis: a long-term retrospective study. Eur Heart J 1991; 12:10–14.
Piper C, Bergemann R, Schulte HD, Koerfer R, Horstkotte D. Can progression of valvar aortic stenosis be predicted accurately? Ann Thorac Surg 2003; 76:676–680.
Nishimura S, Izumi C, Nishiga M, et al. Predictors of rapid progression and clinical outcome of asymptomatic severe aortic stenosis. Circ J 2016; 80:1863–1869.
Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343:611–617.
Nistri S, Faggiano P, Olivotto I, et al. Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care. Am J Cardiol 2012; 109:718–723.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739–2791.
Benfari G, Gori AM, Rossi A, et al. Feasibility and relevance of right parasternal view for assessing severity and rate of progression of aortic valve stenosis in primary care. Int J Cardiol 2017; 240:446–451.
Benfari G, Mantovani F, Romero-Brufau S, et al. The right parasternal window: when Doppler-beam alignment may be life-saving in patients with aortic valve stenosis. J Cardiovasc Med (Hagerstown) 2020; 21:831–834.
Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol 1989; 13:545–550.
Roger VL, Tajik AJ, Bailey KR, Oh JK, Taylor CL, Seward JB. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J 1990; 119 (2 Pt 1):331–338.
Faggiano P, Ghizzoni G, Sorgato A, et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol 1992; 70:229–233.
Brener SJ, Duffy CI, Thomas JD, Stewart WJ. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol 1995; 25:305–310.
Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95:2262–2270.
Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000; 101:2497–2502.
Cowell SJ, Newby DE, Prescott RJ, et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389–2397.
Rossebo AB, Pedersen TR, Boman K, et al. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343–1356.
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306–314.
Nguyen V, Mathieu T, Melissopoulou M, et al. Sex differences in the progression of aortic stenosis and prognostic implication: the COFRASA-GENERAC study. JACC Cardiovasc Imaging 2016; 9:499–501.
Chester AH, El-Hamamsy I, Butcher JT, Latif N, Bertazzo S, Yacoub MH. The living aortic valve: from molecules to function. Glob Cardiol Sci Pract 2014; 2014:52–77.
Mongkoldhumrongkul N, Latif N, Yacoub MH, Chester AH. Effect of side-specific valvular shear stress on the content of extracellular matrix in aortic valves. Cardiovasc Eng Technol 2018; 9:151–157.
Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in nonrheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002; 88:348–351.
Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005; 437:270–274.
Otto CM. Calcification of bicuspid aortic valves. Heart 2002; 88:321–322.
Dweck MR, Jenkins WS, Vesey AT, et al. 18F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. Circ Cardiovasc Imaging 2014; 7:371–378.
Benfari G, Clavel MA, Nistri S, et al. Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow preserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging 2018; 19:569–573.
Magne J, Cosyns B, Popescu BA, et al. Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc Imaging 2019; 12:84–92.
Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 2012; 60:1854–1863.
Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and impact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging 2019; 12:283–296.
Garcia J, Barker AJ, Markl M. The role of imaging of flow patterns by 4D flow MRI in aortic stenosis. JACC Cardiovasc Imaging 2019; 12:252–266.
Otto CM, Prendergast B. Aortic-valve stenosis--from patients at risk to severe valve obstruction. N Engl J Med 2014; 371:744–756.
Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968; 38: (1 Suppl): 61–67.
Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors--a causal relationship? A clinical morphologic study. Clin Cardiol 1991; 14:995–999.
Peter M, Hoffmann A, Parker C, Luscher T, Burckhardt D. Progression of aortic stenosis: role of age and concomitant coronary artery disease. Chest 1993; 103:1715–1719.
Thanassoulis G, Campbell CY, Owens DS, et al. CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368:503–512.
Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 2015; 66:1236–1246.
Marquis-Gravel G, Redfors B, Leon MB, Genereux P. Medical treatment of aortic stenosis. Circulation 2016; 134:1766–1784.
Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol 2015; 66:561–577.
New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res 2011; 108:1381–1391.
Elmariah S, Delaney JA, O’Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 56:1752–1759.
Greve AM, Bang CN, Boman K, et al. Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol 2018; 121:739–745.
Perrot N, Valerio V, Moschetta D, et al. Genetic and in vitro inhibition of PCSK9 and calcific aortic valve stenosis. JACC: Basic to Translational Science 2020; 5:649–661.
Tastet L, Capoulade R, Clavel MA, et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. Eur Heart J Cardiovasc Imaging 2017; 18:70–78.
Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA Cardiol 2018; 3:1060–1068.